Axxcess Wealth Management LLC Acquires 1,529 Shares of Natera, Inc. $NTRA

Key Points

• Axxcess Wealth Management LLC increased its stake in Natera, Inc. by 49% during the second quarter, owning a total of 4,651 shares valued at approximately $786,000.
• Natera reported a net loss of ($0.74) earnings per share for the last quarter, which was a miss compared to analysts' expectations of ($0.60), despite revenue growing by 32.2% year-over-year.
• Insider selling activity has occurred, with executives offloading a combined total of 5,491 shares recently, reflecting a decrease in their ownership positions.

Axxcess Wealth Management LLC raised its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 49.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,651 shares of the medical research company's stock after purchasing an additional 1,529 shares during the quarter. Axxcess Wealth Management LLC's holdings in Natera were worth $786,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in NTRA. GAMMA Investing LLC lifted its holdings in Natera by 32.3% during the first quarter. GAMMA Investing LLC now owns 848 shares of the medical research company's stock valued at $120,000 after purchasing an additional 207 shares in the last quarter. Exchange Traded Concepts LLC lifted its holdings in Natera by 15.6% during the first quarter. Exchange Traded Concepts LLC now owns 6,458 shares of the medical research company's stock valued at $913,000 after purchasing an additional 871 shares in the last quarter. QRG Capital Management Inc. lifted its holdings in Natera by 1.5% during the first quarter. QRG Capital Management Inc. now owns 5,417 shares of the medical research company's stock valued at $766,000 after purchasing an additional 81 shares in the last quarter. Institute for Wealth Management LLC. purchased a new position in Natera during the first quarter valued at approximately $264,000. Finally, ORG Partners LLC purchased a new position in Natera during the first quarter valued at approximately $32,000. Hedge funds and other institutional investors own 99.90% of the company's stock.

Natera Stock Up 0.6%

Natera stock opened at $181.69 on Friday. The company has a market cap of $24.94 billion, a price-to-earnings ratio of -95.13 and a beta of 1.74. The firm's fifty day moving average is $168.19 and its 200 day moving average is $158.35. Natera, Inc. has a 52-week low of $117.27 and a 52-week high of $187.34.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). The business had revenue of $546.60 million for the quarter, compared to analysts' expectations of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. Natera's revenue for the quarter was up 32.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Activity at Natera

In related news, insider Solomon Moshkevich sold 3,000 shares of the company's stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $159.99, for a total transaction of $479,970.00. Following the sale, the insider owned 117,559 shares of the company's stock, valued at $18,808,264.41. This represents a 2.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Michael Burkes Brophy sold 2,491 shares of the company's stock in a transaction on Tuesday, September 30th. The shares were sold at an average price of $162.05, for a total transaction of $403,666.55. Following the sale, the chief financial officer directly owned 69,189 shares in the company, valued at approximately $11,212,077.45. The trade was a 3.48% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 72,464 shares of company stock valued at $10,963,125 over the last quarter. 5.63% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. Morgan Stanley reaffirmed an "overweight" rating and set a $195.00 price target on shares of Natera in a report on Sunday, August 10th. Evercore ISI raised shares of Natera to a "strong-buy" rating and set a $170.00 target price on the stock in a report on Monday, July 28th. Barclays reissued an "overweight" rating and issued a $210.00 target price (up previously from $190.00) on shares of Natera in a report on Friday, August 8th. Stephens reissued an "overweight" rating and issued a $183.00 target price on shares of Natera in a report on Friday, August 15th. Finally, Canaccord Genuity Group reissued a "buy" rating and issued a $200.00 target price on shares of Natera in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $196.81.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.